Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions

Not Applicable

Completed

• Conditions: Ischemic Heart Disease; Kidney Disease, Chronic

• Registration Number: NCT02468401
• Lead Sponsor: Meir Medical Center

Brief Summary

There is a pressing need to find effective strategies for the prevention of contrast induced nephropathy in patients with advanced renal dysfunction. The current study was designed to assess the efficacy of a new protocol for preventing contrast induced nephropathy in patients with advanced renal dysfunction undergoing coronary interventions

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-06-03
• Study First Submitted QC: 2015-06-07
• Study First Posted: 2015-06-10
• Study Start: 2015-09
• Primary Completion: 2016-08
• Study Completion: 2016-08
• Status Verified: 2016-11
• Last Update Submitted: 2016-11-19
• Last Update Posted: 2016-11-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Patients with estimated glomerular filtration rate<45ml/min undergoing coronary angiography due to one of the following indications in accordance with the 2014 guidelines:

1. Elective coronary angiography due to symptoms suggestive for angina with a positive non-invasive ischemia assessment of ≥10% of left ventricle.
2. Non ST-elevation acute coronary syndrome with a GRACE score>110

Exclusion Criteria

• Patients on dialysis or those planned for dialysis in the next 3 months.
• Patients with ST-elevation myocardial infarction
• No symptoms or signs of heart failure
• Treatment with IV diuretics during the 48 hours prior to enrolment
• Patients with acute renal failure (Creatinine raise of at least 0.3mg/dl from )baseline
• Patients post coronary artery bypass surgery

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Changes in glomerular filtration rate following coronary angiography or intervention	24 and 48 hours post procedure	Significant changes are defined as a reduction ≥25% in glomerular filtration rate

Trial Locations

Locations (1)

Meir Medical Center; 🇮🇱 Kfar Saba, Israel